Vaxcyte
PCVX
328 hedge funds and large institutions have $15.6B invested in Vaxcyte in 2024 Q3 according to their latest regulatory filings, with 84 funds opening new positions, 131 increasing their positions, 87 reducing their positions, and 20 closing their positions.
320% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 20
68% more capital invested
Capital invested by funds: $9.26B → $15.6B (+$6.33B)
53% more funds holding in top 10
Funds holding in top 10: 15 → 23 (+8)
51% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 87
48% more call options, than puts
Call options by funds: $90.6M | Put options by funds: $61.4M
24% more funds holding
Funds holding: 265 → 328 (+63)
0.59% less ownership
Funds ownership: 112.66% → 112.07% (-0.59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$185M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$148M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$117M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$91.8M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$89.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$46M |
| 2 |
O
OrbiMed
New York
|
-$36.9M |
| 3 |
CC
Commodore Capital
New York
|
-$34.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$33M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$32.1M |
PCVX Hedge Fund Activity: Q3 2024 in Review
328 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q3 2024, worth a combined $15.6B — up 68% from $9.26B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new PCVX positions and 20 closed out — a net gain of 64 holders — while 131 added to existing stakes and 87 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $185M. The largest seller was Braidwell, cutting an estimated $46M.
- 328 institutional investors held Vaxcyte (PCVX) as of Q3 2024, up from 265 in Q2 2024.
- Funds reported $15.6B of Vaxcyte stock for Q3 2024, up 68% quarter-over-quarter.
- 84 funds opened new Vaxcyte positions in Q3 2024 and 20 closed out, a net change of +64 holders.
- The largest Vaxcyte buyer in Q3 2024 was Janus Henderson Group, an estimated $185M added.
- The largest Vaxcyte seller in Q3 2024 was Braidwell, an estimated $46M sold.
Based on aggregated 13F filings for Q3 2024.